<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061641</url>
  </required_header>
  <id_info>
    <org_study_id>TPB 2021</org_study_id>
    <nct_id>NCT05061641</nct_id>
  </id_info>
  <brief_title>Prediction and Prevention of Twin Premature Birth 2021</brief_title>
  <official_title>Study on the Prediction and Prevention of Twin Premature Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caixia Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research Objectives:&#xD;
&#xD;
        1. Establish a prediction and scoring system for twin premature birth.&#xD;
&#xD;
        2. To investigate the curative effect of 200mg,400mg and 600mg of vaginal progesterone in&#xD;
           the prevention of twin premature birth.&#xD;
&#xD;
        3. To investigate the effect of stress cervical ligation in preventing premature delivery&#xD;
           of twins.&#xD;
&#xD;
        4. The optimal dose of atosiban for the treatment of twin premature birth.&#xD;
&#xD;
        5. The influence of delivery mode on twin premature infants under 32 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Objectives:&#xD;
&#xD;
        1. Establish a prediction and scoring system for twin premature birth.&#xD;
&#xD;
        2. To investigate the curative effect of 200mg,400mg and 600mg of vaginal progesterone in&#xD;
           the prevention of twin premature birth.&#xD;
&#xD;
        3. To investigate the effect of stress cervical ligation in preventing premature delivery&#xD;
           of twins.&#xD;
&#xD;
        4. The optimal dose of atosiban for the treatment of twin premature birth.&#xD;
&#xD;
        5. The influence of delivery mode on twin premature infants under 32 weeks. It has now&#xD;
           entered the second phase: clinical data collection&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The participants and the treating physicians were not informed of the grouping</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal prognosis</measure>
    <time_frame>one week</time_frame>
    <description>Preterm birth rate (&lt;37 weeks of gestation), early preterm birth rate (&lt;32 weeks of gestation), need to receive anti-tocolytic treatment; Rates of premature rupture of membranes (&lt;37 weeks), neonatal perinatal mortality and morbidity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age and prolongation of gestational age at delivery</measure>
    <time_frame>one year</time_frame>
    <description>Gestational age at which symptoms of preterm birth occur and gestational age at delivery after treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>progesterone 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each group was given prophylactic vaginal progesterone up to 34 weeks of gestation，Vaginal progesterone 600mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>The delivery outcomes of the three groups were compared, including the rate of premature delivery (&lt;37 weeks of gestation), the rate of early premature delivery (&lt;32 weeks of gestation), and the need for anti-tocolysis treatment. Rates of premature rupture of membranes (&lt;37 weeks), neonatal perinatal mortality and morbidity.</description>
    <arm_group_label>progesterone 200mg</arm_group_label>
    <arm_group_label>progesterone 400mg</arm_group_label>
    <arm_group_label>progesterone 600mg</arm_group_label>
    <other_name>surgical treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        twins with cervical length ≤ 25 mm by vaginal ultrasound at 14-32 weeks no contractions,&#xD;
        abdominal pain and vaginal bleeding No complicated twin complications occurred during&#xD;
        pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients undergoing selective cervical ligation before 14 weeks of gestation history of&#xD;
        liver problems or cholestasis during pregnancy Abnormal liver enzymes Abnormal renal&#xD;
        function Local allergy to trace natural progesterone Recurrent vaginal bleeding Recurrent&#xD;
        vaginal infection Ultrasound diagnosis of fetal abnormality Intrauterine treatment for&#xD;
        fetal abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei jun, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>1050880483@qq.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu caixia, Dr</last_name>
    <phone>18940251716</phone>
    <email>liucx1716@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>caixia Liu</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu caixia, professor</last_name>
      <phone>86-024-96615</phone>
      <phone_ext>10027</phone_ext>
      <email>18940252882@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Caixia Liu</investigator_full_name>
    <investigator_title>Shengjing hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

